Literature DB >> 10226749

Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III.

W Krivit1, C Peters, E G Shapiro.   

Abstract

Over 400 patients with lysosomal and peroxisomal storage diseases have received hematopoietic stem cell transplantation from normal donors. Without treatment, all of these diseases have an inexorable fate leading to central nervous system deterioration and early death. On the other hand, all of the engrafted hosts have had a remarkable positive clinical improvement in response to normalization of previously deficient enzymatic activity. Survival data for those engrafted indicates continued life-span as long as two decades beyond transplantation. The particular diseases treated in this way are included in this article. The specific indications and methods for transplantation are also included in this article.

Entities:  

Mesh:

Year:  1999        PMID: 10226749     DOI: 10.1097/00019052-199904000-00007

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  56 in total

Review 1.  Evaluation of therapy of X-linked adrenoleukodystrophy.

Authors:  Hugo W Moser; Ali Fatemi; Kathleen Zackowski; Seth Smith; Xavier Golay; Larry Muenz; Gerald Raymond
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

2.  A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA.

Authors:  Elsa G Shapiro; Igor Nestrasil; Kathleen A Delaney; Kyle Rudser; Victor Kovac; Nitin Nair; Charles W Richard; Patrick Haslett; Chester B Whitley
Journal:  J Pediatr       Date:  2016-01-16       Impact factor: 4.406

Review 3.  Gene therapy for metachromatic leukodystrophy.

Authors:  Jonathan B Rosenberg; Stephen M Kaminsky; Patrick Aubourg; Ronald G Crystal; Dolan Sondhi
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

4.  Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease.

Authors:  Akira Yamaguchi; Kayoko Katsuyama; Kyoko Suzuki; Kenji Kosaka; Ichiro Aoki; Shoji Yamanaka
Journal:  J Mol Med (Berl)       Date:  2003-02-12       Impact factor: 4.599

5.  Proteolytic processing of the gamma-subunit is associated with the failure to form GlcNAc-1-phosphotransferase complexes and mannose 6-phosphate residues on lysosomal enzymes in human macrophages.

Authors:  Sandra Pohl; Stephan Tiede; Katrin Marschner; Marisa Encarnação; Monica Castrichini; Katrin Kollmann; Nicole Muschol; Kurt Ullrich; Sven Müller-Loennies; Thomas Braulke
Journal:  J Biol Chem       Date:  2010-05-19       Impact factor: 5.157

6.  Determinants of health care use in a population-based leukodystrophy cohort.

Authors:  Clint Nelson; Michael B Mundorff; E Kent Korgenski; Cameron J Brimley; Rajendu Srivastava; Joshua L Bonkowsky
Journal:  J Pediatr       Date:  2012-10-13       Impact factor: 4.406

Review 7.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

Review 8.  Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.

Authors:  Shannon L Macauley
Journal:  Pediatr Endocrinol Rev       Date:  2016-06

9.  Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases.

Authors:  David G Nathan; Stuart H Orkin
Journal:  Genome Med       Date:  2009-12-09       Impact factor: 11.117

10.  alpha-L-iduronidase therapy for mucopolysaccharidosis type I.

Authors:  Jakub Tolar; Paul J Orchard
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.